Your search returned 7 results.

Results
	1.	Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic. [electronic resource] by Durbin, Anna P Schmidt, Alexander Elwood, Dan Wanionek, Kimberli A Lovchik, Janece Thumar, Bhavin Murphy, Brian R Whitehead, Stephen S Producer: 20110211 In: The Journal of infectious diseases vol. 203 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. [electronic resource] by Durbin, Anna P McArthur, Julie Marron, Jennifer A Blaney, Joseph E Thumar, Bhavin Wanionek, Kim Murphy, Brian R Whitehead, Stephen S Producer: 20061026 In: Human vaccines vol. 2 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. [electronic resource] by Durbin, Anna P Whitehead, Stephen S McArthur, Julie Perreault, John R Blaney, Joseph E Thumar, Bhavin Murphy, Brian R Karron, Ruth A Producer: 20050324 In: The Journal of infectious diseases vol. 191 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	4.	rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults. [electronic resource] by Durbin, Anna P McArthur, Julie H Marron, Jennifer A Blaney, Joseph E Thumar, Bhavin Wanionek, Kimberli Murphy, Brian R Whitehead, Stephen S Producer: 20070206 In: Human vaccines vol. 2 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	5.	A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial. [electronic resource] by Durbin, Anna P Whitehead, Stephen S Shaffer, Donna Elwood, Dan Wanionek, Kimberli Thumar, Bhavin Blaney, Joseph E Murphy, Brian R Schmidt, Alexander C Producer: 20120119 In: PLoS neglected tropical diseases vol. 5 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	6.	Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity. [electronic resource] by McArthur, Julie H Durbin, Anna P Marron, Jennifer A Wanionek, Kimberli A Thumar, Bhavin Pierro, Dennis J Schmidt, Alexander C Blaney, Joseph E Murphy, Brian R Whitehead, Stephen S Producer: 20081124 In: The American journal of tropical medicine and hygiene vol. 79 Availability: No items available. Save to lists Add to cart (remove)
	7.	Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers. [electronic resource] by Wright, Peter F Durbin, Anna P Whitehead, Stephen S Ikizler, Mine R Henderson, Susan Blaney, Joseph E Thumar, Bhavin Ankrah, Sharon Rock, Michael T McKinney, Brett A Murphy, Brian R Schmidt, Alexander C Producer: 20091117 In: The American journal of tropical medicine and hygiene vol. 81 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)